UK-BCM-220070. DOP: April 2022.
Chronic migraine: a long and frustrating patient journey5†
Diagnosing and managing chronic migraine
Could your patients with chronic migraine benefit from treatment with BOTOX®?*
A real-life patient treatment journey
Kayte was diagnosed with chronic migraine at 24, and experienced issues with certain treatments before finding one that suited her.
Learn about her individual experience in this video, and find out about her experience with BOTOX® >
Initiating a patient on BOTOX®
How should you consult your patients who are starting on BOTOX®, and how can you ensure treatment adherence?
Neurologist Dr Andrew Blumenfeld explains in this 6-minute video >
CM: chronic migraine; CV: cardiovascular; ICHD: International Classification of Headache Disorders.
*BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).14
References
- Allergan. Data on file. INT/0423/2016
- Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
- Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
- Allergan Ltd. Data on file 014
- Davies P T G, Lane R J M et al. The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev 2019;20:e4
- Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30(5):599-609
- National Institute for Health and Care Excellence (NICE). CG150: Headaches in over 12s: diagnosis and management. Available at: www.nice.org.uk. Accessed April 2022
- Schwedt T J. Chronic migraine. BMJ 2014;348:g1416
- National Institute of Health and Care Excellence (NICE) clinical knowledge summary (CKS). Migraine. Available at: https://cks.nice.org.uk. Accessed April 2022
- Buse D C, Manack A N et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(10):1456-1470
- Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 2018;58(Suppl 3):218-229
- Woolley J M, Bonafede M M et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 2017;57(9):1399-1408
- Blumenfeld A M, Silberstein S D et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache 2017;57(5):766-777
- BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022
- International Headache Society (IHS). International classification of headache disorders (3rd edition) guidelines. Available at: www.ihs-headache.org. Accessed April 2022
- Aurora S K, Brin M F. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache 2017;57(1):109-125
- Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 2015;6(3):115-123
- Lipton R B. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011;51 Suppl 2:77-83
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
Date of preparation: April 2022. UK-BCM-220072.
